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characteristics as well as procedural and clinical outcomes among patients with severe
aortic stenosis undergoing TAVI.
Methods: Between July 2007 and September 2010, a total of 256 high-risk patients with
severe aortic stenosis were prospectively included in a single-center registry. Patients
underwent TAVI using transfemoral or transapical access with the use of both CE
approved devices, the Edwards Sapien and Medtronic Corevalve prosthesis, depending on
anatomic and technical requirements.
Results: Out of 256 patients, 112 patients were male (44%) and 144 patients (56%)
female. Females were older (845 vs. 817, p0.01) presented with a smaller body
surface area (1.70.2 vs. 1.90.2, p0.01) and were less likely to have hypercholester-
olemia (54% vs. 68%, p0.03), coronary artery disease (54% vs. 80%, p0.01), prior
coronary artery bypass graft surgery (9% vs. 37%, p0.01) and chronic obstructive
pulmonary disease (25% vs. 13%, p0.022). Baseline echocardiographic assessment
revealed smaller aortic valve area (0.490.2cm2 vs. 0.650.3 cm2, p0.01) in female
patients but a similar ejection fraction (52.316 vs. 49.115, pns). Preoperative risk
assessment by means of the logistic EuroScore showed no differences (24.8%15 vs.
24.7%15, pns), whereas the STS risk score predicted a higher mortality (7.0%5
vs.5.7%5, p0.034) among female patients. Follow up assessment at 30days demon-
strated no difference in clinical outcome in terms of 30-day mortality (5.4% vs. 7.6%,
pns), stroke (5.4% vs. 2.8%, pns), RIFLE stage 3 kidney injury (3.6% vs. 3.5%,
pns) and life-threatening bleeding (12.5% vs. 10.4%, pns) between both groups. The
VARC combined safety endpoint occurred among 22.3% male and 18.1% female patients
(pns).
Conclusions: Although there are important differences in baseline clinical characteristics
between male and female patients undergoing TAVI, short-term clinical outcome is
similar in terms of mortality and the VARC composite safety endpoint.
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Background: The PARTNER Trial demonstrated that, in patients with severe symp-
tomatic aortic stenosis (AS) deemed too high risk for surgery, transcatheter aortic valve
replacement (TAVR) reduces mortality compared to standard therapy (ST). Whether there
are gender-specific differences in outcomes of TAVR in this population is unknown.
Methods: Data were drawn from the cohort of 192 women (53.6%) and 166 men
(46.4%) enrolled in Cohort B of the PARTNER Trial (TAVR vs. ST). Outcomes were
assessed using intent-to-treat analyses, and were compared between the two treatment
groups, with follow-up to 2 years.
Results: Compared with men, women had a higher median STS scores (11.7 vs. 10.8,
p0.01), but were less frequently smokers, and less frequently had coexisting coronary
artery disease. Women had lower median creatinine, but similar creatinine clearance
compared to men. Hemodynamic findings at baseline differed among women and men;
women had higher ejection fractions and systolic blood pressures. In women and men,
there were no appreciable differences across randomized treatment groups. At 30 days,
there was a greater rate of periprocedural bleeding and vascular complications among
women treated with TAVR compared to ST, and a numerically, but not statistically,
higher rate of mortality and (predominantly minor) stroke. However, at 1 year, women
treated with TAVR had a 46% lower rate of mortality and a 70% lower rate of repeat
hospitalization compared to ST (Table); these findings were maintained at 2 years. There
was no significant treatment-gender interaction for any of these outcomes.
Conclusions: Women represented a majority of patients enrolled in Cohort B of the
PARTNER trial (192/358 patients). Despite observed differences in comorbidities and
hemodynamic characteristics among women and men enrolled in the trial, the mortality
benefit of TAVR over ST observed in the overall trial cohort was preserved in women.
Table: 2 year outcomes stratified by patient gender
Female Male
TAVR ST P TAVR ST P
P
Int
Death 44.6%
(43)
63.9%
(59)
0.008 41.6%
(34)
72.8%
(59)
0.0002 0.45
Repeat
hospitalization
29.6%
(23)
70.0%
(52)
0.001 31.2%
(22)
74.4%
(41)
0.0001 0.53
Stroke 16.4%
(14)
9.2%
(7)
0.17 10.6%
(8)
1.2%
(1)
0.02 0.22
Minor 10.3%
(9)
7.8%
(6)
0.53 5.2%
(4)
0.0%
(0)
0.04 0.99
Major 2.1%
(2)
0.0%
(0)
0.16 4.3%
(3)
1.2%
(1)
0.36 1.00
Major bleeding 29.2%
(27)
22.1%
(16)
0.09 28.6%
(21)
15.9%
(8)
0.02 0.37
Vascular
complications
40.3%
(39)
10.9%
(9)
0.001 23.4%
(19)
7.0%
(5)
0.002 0.73
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Background: For patients with severe symptomatic AS, TAVR has been associated with
improved outcomes compared to medical therapy, and non-inferior outcomes compared
to conventional AVR. Concerns have been raised, however, about a subset of patients who
may survive the procedure itself but for whom a short duration of survival in the months
after the procedure may have rendered this costly intervention potentially “futile”.
Methods: All PARTNER patients undergoing TAVR and surviving 30 days post
procedure were categorized as those who survived 12 months (short survivors (SS)
n106), or 12 months (long survivors (LS), n384). Pre-procedural characteristics of
SS were compared with those of LS; independent predictors of SS were identified through
multivariable analyses.
Results: Compared to LS, SS after TAVR had higher STS scores (12.0 vs. 11.0, p0.01),
lower BMI, lower mini-mental status exam scores, more frequently had undergone prior
balloon aortic valvuloplasty, and more frequently had coexisting kidney or liver disease.
The need for IABP/hemodynamic support during TAVR was also more frequent among
SS patients. There were no significant differences in baseline echo parameters among SS
and LS. Independent predictors of SS are shown in Table; the majority of these were
weakly associated with ultimate SS. As expected, SS more frequently (p0.001)
experienced post-procedural complications after TAVR, including stroke (19.8% vs.
5.0%) and renal failure requiring dialysis (14.4% vs. 1.3%).
Table: Independent Correlates of SS
Independent Correlates of SS Hazard Ratio p value
Hemodynamic Support During TAVR 3.77 [1.73, 8.22] 0.001
Creatinine 2 mg/dl 1.06 [1.00, 1.11] 0.039
Diabetes Mellitus 0.54 [0.35, 0.84] 0.006
Prior Liver disease 4.11 [1.74, 9.68] 0.001
Total Mini Mental State Exam Score 0.94 [0.90, 0.99] 0.022
Prior Renal Disease 1.60 [1.02, 2.51] 0.041
STS Risk Score 1.08 [1.03, 1.12] 0.001
Conclusions: Among high risk or inoperable patients undergoing TAVR, it is difficult to
identify pre-procedural clinical factors that can reliably predict survival30 days beyond
the procedure but lasting 12 months. In contrast, attempts to minimize periprocedural
complications will likely have the greatest impact in preventing SS after TAVR.
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